AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
Innoplexus Launches Worldwide Academic Access Program for its Flagship Ontosight.ai
Frankfurt, Germany, May 21, 2019 — Innoplexus announced today the launch of Ontosight Academic, a platform that provides academic researchers free access to a vast volume of life sciences data made searchable using machine learning algorithms and other artificial intelligence technologies. Today, academic researchers in life sciences are swamped with millions of publications and theses that they use to validate a hypothesis or to find a relevant connection. This research is important because it has the potential to improve quality of life for everyone. For this reason, Innoplexus aims to remove certain limitations to academic research by democratizing data and supporting research conducted by life science academics, thereby facilitating progress in this area. After collaboration with selected universities in the United States since last year, Innoplexus is now launching the academic access program worldwide. The platform is available to academic life sciences researchers at ontosight.ai/academic.
Innoplexus’s Ontosight Academic platform leverages its life science data ocean with a self-learning life sciences-specific ontology along with natural language processing to provide search results that are more industry specific and relevant to the search query. The life sciences ontology developed by Innoplexus enables concept-based contextual and accurate results generated from over 95% of publicly available life sciences data. “Knowledge is growing faster than our ability to effectively absorb and apply it in research. It is estimated that by 2020 the amount of medical knowledge will double every 73 days. What medical students who will graduate that year learned during the first 3 years of their studies will represent only 6% of the knowledge accumulated by the medical world in the decade that ends in 2020,” says Dr. Gunjan Bhardwaj, CEO and founder of Innoplexus. “Therefore, we support researchers to further scientific development by giving them faster and better access to all the data. We are driven by our determination to help science win.”
Innoplexus leverages machine learning algorithms to make this data structured and available for generating useful, real-time insights by academic researchers. With its proprietary technology, which crawls, aggregates, analyzes, and visualizes data from various scientific resources such as publications, clinical trial repositories, drug profiles, gene profiles, theses, dissertations, grants, and patents, Innoplexus ensures access to even the most nascent research being done in their field.
Featured News
Partex and Singapore’s Experimental Drug Development Centre collaborate to bring
Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven
Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to…
Partex NV announces collaboration with Althea DRF Lifesciences to provide
Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF…
Innovative AI technology in oncology: Partex Group presents results from
During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the…
Partex NV Forges Collaboration with Sanofi in AI-Based Dossier Enrichment
Frankfurt, Germany; 14 March 2024 Partex Group, a pioneer in AI-driven drug discovery, today announces a collaboration with global pharmaceutical…
Innoplexus and AIO Studien gGmbH are jointly announcing the start
January 02, 2024 – Innoplexus and Amrit AG, members of the Partex NV Group, providers of innovative technology for health…
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
